$560 | Single User
$1120 | Site License
$1680 | Global License

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

Published by La Merie: 01 May 2016 | 672 | In Stock

Introduction

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update


Humira, Enbrel and Remicade were the three best selling blockbuster biologics in the year 2015. Together with Simponi and Cimzia, combined sales of all five anti-TNF antibodies in the year 2015 were US$ 36 bln (+3.9% vs previous year), ahead of combined sales of all cancer antibodies. Marketing of biosimilar versions of Remicade and Enbrel in Europe has commenced and first sales data indicate that originator and biosimilar anti-TNF antibodies compete for new patients, rather than switching during ongoing treatment.


While the commercial impact of biosimilar anti-TNF antibodies in the year 2015 still was controlled, sales data of the first quarter of 2016 show a 30% loss of Remicade sales in Europe (about US$ 150 mln). Thus, an  accelerating impact of biosimilar competition in Europe can be expected. After approval of the first anti-TNF biosimilar antibody by the FDA in the US, market launch could take place by end of 2016. Even AbbVie’s ‘135 patent for Humira is going to be reviewed by the Patent Trial and Appeal Board of the US Patent and Trademark office, which ultimately could lead to accelerated loss of Humira market exclusivity.


More than 20 different biosimilar anti-TNF antibodies are in phase III development according to EU and US guidelines in regulated markets. As a consequence, the first companies with limited resources are reconsidering their priorities and are evaluating other options.


This Competitive Intelligence report about Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha used to treat inflammatory and autoimmune diseases as of May 201. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active R&D projects of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents
for Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update

Table of Contents

1.         Originator Anti-TNF Antibodies

  • Approved and Marketed Indications of anti-TNF Antibodies in Regulated Markets
  • 2015 Sales of Anti-TNF Antibodies
  • Sales of Anti-TNF Antibodies in Q1/2016
  • Humira Pipeline of Recently Approved Indications & Upside Developments
  • Remicade Pipeline of Recent Approvals & Upside Indications
  • Enbrel Pipeline of Upside Indications
  • Simponi Pipeline of Recent Approvals & Upside Indications
  • Cimzia Pipeline of Recent Approvals & Upside Indications
  • Defense Strategies against Biosimilar Anti-TNF Antibodies

2.         Biosuperior Anti-TNF Antibodies

  • Non-Antibody Anti-TNF Biosuperiors
  • Anti-TNF Biosuperior Antibodies

3.         Biosimimilar Anti-TNF Antibodies

Humira Biosimilar Antibodies:

-           Developments in Regulated Markets

-           Developments in Less Regulated Markets

Enbrel Biosimilar Antibodies:

-           Developments in Regulated Markets

-           Developments in Less Regulated Markets

Remicade Biosimilar Antibodies:

-           Developments in Regulated Markets

-           Developments in Less Regulated Market

Simponi & Cimzia Biosimilar Antibodies

4.         Corporate Anti-TNF Antibody Biosimilar & Biosuperior R&D Pipeline

Additional Details

Publisher

La Merie

Publisher Information

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Reference

672 | LMCA0125

Number of Pages

124

Report Format

PDF

La Merie Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other DiseasesThis Compet...
01 Jun 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel a...
01 May 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitiv...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 UpdateTable of Contents...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 UpdateThis Competitive...
01 May 2016 by La Merie USD $280 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) familyThe Compet...
17 Jan 2016 by La Merie USD $225 More Info
Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?
Scope Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Vie...
11 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?
Scope Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 a...
05 Mar 2014 by FirstWord Pharma USD $695 More Info

This report is published by La Merie

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Download Free Report Summary PDF

Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data